Not Yet RecruitingPhase 3Other

Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery

NCT ID

NCT07414706

Target Enrollment

182 participants

Start Date

2026-03

Est. Completion

2028-09

About This Study

This randomized controlled trial evaluates whether perioperative intravenous lidocaine infusion, combined with port-site ropivacaine infiltration, improves postoperative recovery after laparoscopic abdominal surgery. Participants will be assigned 1:1 to receive either intravenous lidocaine during surgery plus ropivacaine infiltration at surgical closure, or ropivacaine infiltration alone. The primary endpoint is postoperative quality of recovery measured by the QoR-15 questionnaire. Secondary endpoints include postoperative pain and opioid consumption, as well as plasma lidocaine and ropivacaine concentrations to assess systemic exposure and safety.

Conditions Studied

Intravenous LidocaineLaparoscopic SurgeryPost Operative RecoveryLocal Anaesthetic Systemic Toxicity

Interventions

•Procedure/Standard care
•ropivacaine
•Lidocaine (intravenous infusion, perioperative)

Eligibility

Age:18 Years - N/A

Healthy Volunteers:No

View full eligibility criteria

Inclusion Criteria:

* Patient undergoing scheduled colorectal cancer surgery via laparoscopy.
* Patient aged 18 years or older.
* Informed consent obtained and signed.
* Affiliation to a social security system.

Exclusion Criteria:

* Allergy or contraindication to lidocaine or ropivacaine.
* Allergy or contraindication to paracetamol, nefopam ketamine, propofol, dexamethasone, sufentanil, Celebrex or parecoxib, morphine derivatives, and colorectal surgery by laparotomy
* Colorectal surgery with a non-cancerous indication.
* Chronic preoperative pain (defined as persistent pain for more than 3 months).
* Preoperative use of opioids or opioid derivatives.
* Patients with psychiatric disorders.
* Patients for whom self-assessment of pain using a self-reported scale cannot be performed (non-communicative, non-French speaking, etc.).
* Pregnant or breastfeeding women.
* Patients under guardianship, curatorship, or legal protection.

Study Locations (1)

CHU Amiens

Amiens, France